Home / Going-concern warnings / Aura Biosciences, Inc.
Filed 2026-03-30 路 Form 10-K 路 Accession 0001193125-26-130401 small
Price before filing: $6.27 (2026-03-27 close, split/dividend-adjusted)
Market cap at flag: $418.2M (2026-03-30) 路 Latest: $578.7M (2026-10-16)
| Window | AURA | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | +7.3% | +12.2% | -4.9% | 2026-04-29 |
| 90 days | +9.7% | +17.2% | -7.4% | 2026-06-29 |
| 180 days | -1.9% | +21.4% | -23.3% | 2026-09-28 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
90 days before the flag: 5 insiders sold $619K (7 sales)
30 days after: 1 insider sold $82K (1 sale)
| Date | Insider | Type | Shares | Price | Value | 10b5-1 plan | Source |
|---|---|---|---|---|---|---|---|
| 2026-01-20 | Elazzouzi Amy Senior Vice President, Finance | Sale | 1,581 | $4.86 | $8K | no | Form 4 |
| 2026-01-20 | de los Pinos Elisabet See Remarks, Director | Sale | 16,928 | $4.86 | $82K | no | Form 4 |
| 2026-02-17 | Elazzouzi Amy Senior Vice President, Finance | Sale | 8,549 | $5.06 | $43K | no | Form 4 |
| 2026-02-17 | Hopkins Janet Jill Chief Medical Officer | Sale | 20,401 | $5.06 | $103K | no | Form 4 |
| 2026-02-17 | Kilroy Conor See Remarks | Sale | 12,079 | $5.05 | $61K | no | Form 4 |
| 2026-02-17 | Plavsic Mark Chief Technology Officer | Sale | 15,890 | $5.05 | $80K | no | Form 4 |
| 2026-02-17 | de los Pinos Elisabet See Remarks, Director | Sale | 47,648 | $5.06 | $241K | no | Form 4 |
| 2026-03-30: red flag filed | |||||||
| 2026-04-16 | Kilroy Conor See Remarks | Sale | 11,738 | $7.02 | $82K | no | Form 4 |
Open-market purchases and sales (Form 4 codes P and S) by officers, directors and 10% owners, by transaction date, from 2025-12-30 to 2026-04-29. Excludes option exercises, grants, gifts and tax withholding. Amended filings replace the originals; joint filings count once. Foreign private issuers do not file Form 4. Many insider sales are pre-scheduled (10b5-1 plans) and are not by themselves a sign of wrongdoing.
"Based on our current operating plan, we believe there is substantial doubt about our ability to continue as a going concern for at least twelve months following the filing of this Annual Report on Form 10-K, and we will need to obtain additional funding."
Quoted from the filing. Source
The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.
Source: management disclosure in Form 10-K (period 2025-12-31)
Read the original filing on SEC.gov →
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Subscribe to the newsletter →
The signup form didn't load here (often an ad or privacy blocker). This opens beehiiv's secure signup page.
Form not showing? Subscribe on beehiiv →
Newsletter delivered by beehiiv. See our privacy policy.